- Home
- CHRS vs DHF Comparison
CHRS vs DHF Comparison
Compare CHRS & DHF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- DHF
- Stock Information
- Founded
- CHRS 2010
- DHF 1998
- Country
- CHRS United States
- DHF United States
- Employees
- CHRS 235
- DHF N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- DHF Finance Companies
- Sector
- CHRS Health Care
- DHF Finance
- Exchange
- CHRS Nasdaq
- DHF Nasdaq
- Market Cap
- CHRS 134.4M
- DHF 188.4M
- IPO Year
- CHRS 2014
- DHF N/A
- Fundamental
- Price
- CHRS $1.16
- DHF $2.60
- Analyst Decision
- CHRS Strong Buy
- DHF
- Analyst Count
- CHRS 4
- DHF 0
- Target Price
- CHRS $5.38
- DHF N/A
- AVG Volume (30 Days)
- CHRS 2.4M
- DHF 451.1K
- Earning Date
- CHRS 03-12-2025
- DHF 01-01-0001
- Dividend Yield
- CHRS N/A
- DHF 7.65%
- EPS Growth
- CHRS N/A
- DHF N/A
- EPS
- CHRS N/A
- DHF N/A
- Revenue
- CHRS $304,340,000.00
- DHF N/A
- Revenue This Year
- CHRS $2.47
- DHF N/A
- Revenue Next Year
- CHRS N/A
- DHF N/A
- P/E Ratio
- CHRS N/A
- DHF N/A
- Revenue Growth
- CHRS 44.19
- DHF N/A
- 52 Week Low
- CHRS $0.66
- DHF $2.06
- 52 Week High
- CHRS $2.87
- DHF $2.39
- Technical
- Relative Strength Index (RSI)
- CHRS 38.01
- DHF 53.08
- Support Level
- CHRS $1.03
- DHF $2.53
- Resistance Level
- CHRS $1.39
- DHF $2.62
- Average True Range (ATR)
- CHRS 0.14
- DHF 0.03
- MACD
- CHRS -0.03
- DHF 0.00
- Stochastic Oscillator
- CHRS 14.04
- DHF 50.00
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.
About DHF BNY Mellon High Yield Strategies Fund
BNY Mellon High Yield Strategies Fund is a diversified, closed-end management investment company. The fund's primary investment objective is to seek high current income and its secondary objective is capital appreciation. It invests predominantly in fixed-income securities of below-investment-grade credit quality.